AMGEN IN EUROPE

ABOUT

Amgen (Nasdaq: AMGN) is committed to unlocking the potential of biology for patients suffering from serious illnesses by discovering, developing, manufacturing and delivering innovative human therapeutics. This approach begins by using tools like advanced human genetics to unravel the complexities of disease and understand the fundamentals of human biology. AMGEN MISSIO N

Amgen focuses on areas of high unmet medical need and leverages its biologics To Serve Patients manufacturing expertise to strive for solutions that improve health outcomes and dramatically improve people’s lives. A biotechnology pioneer since 1980, Amgen has grown to be one of AMGEN QUICK FACTS the world’s leading independent biotechnology companies, has reached millions of patients European Hub around the world and is developing a pipeline of medicines with breakaway potential. Rotkreuz, Switzerland Amgen Europe was established in 1989 and today comprises more than 4000 employees engaged in assisting patients across 31 countries in Europe. The European Hub in Rotkreuz, Address/Phone Switzerland, employs more than 200 staff members. Amgen’s Swiss affiliate is located in the Amgen (Europe) GmbH neighboring building and was established shortly after the Amgen European Commercial Suurstoffi 22 headquarters in 1989. Today, the Swiss branch employees around 100 staff members. 6343, Rotkreuz

Switzerland INNOVATIVE MEDICINES T: +41 41 369 0300 We have a presence in approximately 100 countries worldwide and our innovative medicines F: +41 41 369 0400 have reached millions of people in the fight against serious illnesses. We focus on six therapeutic areas: cardiovascular disease, oncology, bone health, neuroscience, nephrology and inflammation. Our medicines typically address diseases for which there are limited treatment options, or they are medicines that provide a viable option to what is otherwise available. PRODUCTS available in Europe:

Amgevita® (adalimumab) EUROPEAN MARKET PRESENCE Aranesp® () Amgen helps patients in the following locations: BLINCYTO® (blinatumomab) Austria France Latvia Russia & CIS IMLYGICTM (talimogene Belgium Germany Lithuania Slovakia laherparepvec) Bulgaria Greece Luxembourg Slovenia Kanjinti® (trastuzumab) ® Croatia Hungary Netherlands Spain Kyprolis (carfilzomib) ® Czech Republic Iceland Norway Sweden Mimpara (cinacalcet) MVASI® (bevacizumab-awwb) Denmark Ireland Poland Switzerland Neulasta® () Estonia Israel Portugal United Kingdom NEUPOGEN® () Finland Italy Romania Parsabiv™ (etelcalcetide)

Nplate® (romiplostim) Prolia® () Repatha® (evolocumab) Vectibix® (panitumumab) XGEVA® (denosumab)

For information about our pipeline and therapies, visit www.amgen.com.

Last updated (March 2019)

NEXT GENERATION OFFICE CONCEPT Thus far, several offices in Europe have converted to Next Generation spaces and Switzerland is now one of them. In summer 2018, the European Hub and Swiss Affiliate launched into full operation from Rotkreuz. Our offices are located at the newly developing Suurstoffi area of Rotkreuz in one of the country’s first-ever wooden high rises.

The open space concept fosters an environment that promotes engagement among employees, encourages cross-functional collaboration, and allows people and their ideas to flow more freely. The design invites movement and choice to suit employees’ needs throughout the day, thus offers different types of spaces: scrum-style tables for teamwork, piazzas for quick team meetings, focus rooms for quiet work and social hubs for interacting. Equipped with state-of-the-art technology, there are plenty of opportunities to help shape innovative solutions as a team.

GREAT PLACE TO WORK In 2018 for the first time ever, Amgen’s Swiss Affiliate participated in the Great Place to Work® (GPTW) awards. Its efforts resulted in a seventh-place overall win, and a first-place win among biopharma firms in Switzerland with 50-249 employees.

“We are very proud to be awarded the best biopharma company in our category,” says General Manager Henrik Asmussen. “This motivates us to become an even better place to work next year by engaging our employees on addressing the issues where we can improve.”

In addition the European Hub was awarded GPTW in 2019, ranking details will be published in April 2019.

These awards are especially meaningful as they are primarily driven by the judgement of our own employees, whose opinion makes up the largest portion of the overall rating. The ongoing drive for innovation helps Amgen and our employees to develop and challenge ourselves.

THE AMGEN FOUNDATION The Amgen Foundation seeks to advance excellence in science education to inspire the next generation of innovators, and invest in strengthening communities where Amgen staff members live and work. To date, the Foundation has donated more than $250 million in grants to local, regional and international nonprofit organizations that impact society in inspiring and innovative ways. The Amgen Foundation brings the excitement of discovery to the scientists of tomorrow through several signature programs, including Amgen Scholars, Amgen Biotech Experience and Amgen Teach. For AMGEN VALUES more information, visit www.AmgenInspires.com.

• Be Science-Based • Compete Intensely and Win CAREERS AT AMGEN • Create Value for Patients, Staff and If you’re seeking a career where you can truly make a difference in the lives of others, a career where Stockholders you can work at the absolute forefront of biotechnology with the top minds in the field, you’ll find it at • Be Ethical Amgen. • Trust and Respect Each Other • Ensure Quality As an organization dedicated to improving the quality of life for people around the globe, Amgen • Work in Teams fosters an inclusive environment of diverse, committed and highly accomplished people. People who • Collaborate, Communicate and Be respect each other but compete intensely to win. Together, we live the Amgen Values as we Accountable continue advancing science to serve patients.

EUHQ-C-NPS-0617-051062(2)